Related references
Note: Only part of the references are listed.Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?
Dario Giugliano et al.
DIABETES OBESITY & METABOLISM (2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Lawrence A. Leiter et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke Post Hoc Analysis From the LEADER Trial
Subodh Verma et al.
CIRCULATION (2018)
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETOLOGIA (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis
P. Gargiulo et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2017)
Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?
David J. Fisher et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?
David J. Fisher et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes
James J. Chamberlain et al.
ANNALS OF INTERNAL MEDICINE (2016)
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
Marina V. Basalay et al.
CARDIOVASCULAR RESEARCH (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Julio Rosenstock et al.
DIABETES CARE (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an Endothelial Resistance to Glucagon-Like Peptide 1 in Diabetes
Antonio Ceriello et al.
DIABETES CARE (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Share Paper
